PREDICT-RT
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- NCT04513717 ↗
- Active, not recruiting
- NRG Oncology
- Standard
We haven't built an HCP commentary report on PREDICT-RT (apalutamide, bicalutamide and 8 more in Prostate Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PREDICT-RT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 7 | |
| YouTube | 4 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
- Arms
- Arm I (de-intensification study) · Active comparator
- Arm II (de-intensification study) · Experimental
- Arm III (intensification study) · Active comparator
- Arm IV (intensification study) · Experimental
- Enrollment
- 2,753
- Primary outcomes
- Metastasis-free survival (MFS)
- Sexual quality of life (De-intensification study)
- Hormonal quality of life (De-intensification study)
- Fatigue (Intensification study)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Jan 21, 2021
- Primary completion
- Dec 31, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT04513717 · updated Aug 17, 2026